80 related articles for article (PubMed ID: 18776245)
1. Potent single stranded RNA inhibition.
Koch T
Nucleic Acids Symp Ser (Oxf); 2008; (52):45. PubMed ID: 18776245
[TBL] [Abstract][Full Text] [Related]
2. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.
Elmén J; Thonberg H; Ljungberg K; Frieden M; Westergaard M; Xu Y; Wahren B; Liang Z; Ørum H; Koch T; Wahlestedt C
Nucleic Acids Res; 2005; 33(1):439-47. PubMed ID: 15653644
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of microRNA with antisense oligonucleotides.
Esau CC
Methods; 2008 Jan; 44(1):55-60. PubMed ID: 18158133
[TBL] [Abstract][Full Text] [Related]
4. On the in vitro and in vivo properties of four locked nucleic acid nucleotides incorporated into an anti-H-Ras antisense oligonucleotide.
Fluiter K; Frieden M; Vreijling J; Rosenbohm C; De Wissel MB; Christensen SM; Koch T; Ørum H; Baas F
Chembiochem; 2005 Jun; 6(6):1104-9. PubMed ID: 15861430
[TBL] [Abstract][Full Text] [Related]
5. An LNA-based loss-of-function assay for micro-RNAs.
Naguibneva I; Ameyar-Zazoua M; Nonne N; Polesskaya A; Ait-Si-Ali S; Groisman R; Souidi M; Pritchard LL; Harel-Bellan A
Biomed Pharmacother; 2006 Nov; 60(9):633-8. PubMed ID: 16962735
[TBL] [Abstract][Full Text] [Related]
6. Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates.
Straarup EM; Fisker N; Hedtjärn M; Lindholm MW; Rosenbohm C; Aarup V; Hansen HF; Ørum H; Hansen JB; Koch T
Nucleic Acids Res; 2010 Nov; 38(20):7100-11. PubMed ID: 20615897
[TBL] [Abstract][Full Text] [Related]
7. Functional comparison of single- and double-stranded siRNAs in mammalian cells.
Xu Y; Linde A; Larsson O; Thormeyer D; Elmen J; Wahlestedt C; Liang Z
Biochem Biophys Res Commun; 2004 Apr; 316(3):680-7. PubMed ID: 15033453
[TBL] [Abstract][Full Text] [Related]
8. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA.
Vester B; Wengel J
Biochemistry; 2004 Oct; 43(42):13233-41. PubMed ID: 15491130
[TBL] [Abstract][Full Text] [Related]
9. Nuclease resistant methylphosphonate-DNA/LNA chimeric oligonucleotides.
Nagahama K; Veedu RN; Wengel J
Bioorg Med Chem Lett; 2009 May; 19(10):2707-9. PubMed ID: 19375912
[TBL] [Abstract][Full Text] [Related]
10. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
[TBL] [Abstract][Full Text] [Related]
11. The application of locked nucleic acids in the treatment of cancer.
Frieden M; Orum H
IDrugs; 2006 Oct; 9(10):706-11. PubMed ID: 17016778
[TBL] [Abstract][Full Text] [Related]
12. The utility of LNA in microRNA-based cancer diagnostics and therapeutics.
Stenvang J; Silahtaroglu AN; Lindow M; Elmen J; Kauppinen S
Semin Cancer Biol; 2008 Apr; 18(2):89-102. PubMed ID: 18295505
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of multiple-turnover capability of locked nucleic acid antisense oligonucleotides in cell-free RNase H-mediated antisense reaction and in mice.
Yamamoto T; Fujii N; Yasuhara H; Wada S; Wada F; Shigesada N; Harada-Shiba M; Obika S
Nucleic Acid Ther; 2014 Aug; 24(4):283-90. PubMed ID: 24758560
[TBL] [Abstract][Full Text] [Related]
14. Locked nucleic acids: promising nucleic acid analogs for therapeutic applications.
Veedu RN; Wengel J
Chem Biodivers; 2010 Mar; 7(3):536-42. PubMed ID: 20232325
[TBL] [Abstract][Full Text] [Related]
15. LNA-modified oligonucleotides mediate specific inhibition of microRNA function.
Ørom UA; Kauppinen S; Lund AH
Gene; 2006 May; 372():137-41. PubMed ID: 16503100
[TBL] [Abstract][Full Text] [Related]
16. Fine tuning of electrostatics around the internucleotidic phosphate through incorporation of modified 2',4'-carbocyclic-LNAs and -ENAs leads to significant modulation of antisense properties.
Zhou C; Liu Y; Andaloussi M; Badgujar N; Plashkevych O; Chattopadhyaya J
J Org Chem; 2009 Jan; 74(1):118-34. PubMed ID: 19055352
[TBL] [Abstract][Full Text] [Related]
17. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
18. Mipomersen.
Am J Cardiovasc Drugs; 2010; 10(4):271-9. PubMed ID: 20653334
[TBL] [Abstract][Full Text] [Related]
19. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and properties of double-stranded antisense oligonucleotides connected with a pentaerythritol linker.
Shibata A; Ueno Y; Matsuda A; Kitade Y
Nucleic Acids Symp Ser (Oxf); 2006; (50):73-4. PubMed ID: 17150823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
